<DOC>
	<DOCNO>NCT02264028</DOCNO>
	<brief_summary>- To investigate absorption , metabolism excretion [ 14C ] -DK-AH 269 CL oral intravenous administration healthy volunteer - To assess safety tolerability DK-AH 269 CL oral intravenous administration healthy volunteer</brief_summary>
	<brief_title>Metabolism Pharmacokinetics 14C-DK-AH 269 CL 12 Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>50 65 year age Body Mass Index ( BMI ) 19.9 29.9 kg/m2 Resting heart rate ( HR ) ( 5 min . supine position ) 55 bpm All volunteer give write informed consent prior admission study accordance Good Clinical Practice ( GCP ) local legislation . Any finding medical examination ( include BP , HR ECG ) deviate normal clinical relevance Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , hematological/oncological , immunological hormonal disorder Diseases central nervous system psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator Intake drug long halflife ( &gt; 24 hour ) within ten halflives respective drug enrolment study Use drug might influence result trial within two week prior administration trial Participation another trial investigational drug ( ≤ two month prior administration trial ) Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke trial day Alcohol abuse ( &gt; 60 g/day ) Drug abuse Blood donation ( ≥ 100 mL within 2 month prior administration trial ) Excessive physical activity ( within last week study ) Any laboratory value outside reference range clinical relevance Inability comply dietary regimen study centre Not necessarily clinically relevant abnormality , specific exclusion criterion drug study study : Subjects increase risk development cardiac arrhythmia ( e.g . family history long QT syndrome sudden cardiac death ) ECG : PR interval &gt; 210 m HR rest ≤ 55 beat per minute ( bpm ) Relevant ophthalmological disease</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>